kringle-pharmaCo., Ltd.

NEWS

notice


Warning: Invalid argument supplied for foreach() in /home/r3716923/public_html/kringle-pharma.com/wp-content/themes/kringle_pharma/view/single/column.php on line 29
Sep 09, 2021

Kringle Pharma, a late clinical-stage biopharmaceutical company, today announces the World Health Organization (WHO) has published “oremepermin alfa” as the recommended International Nonproprietary Name (INN) for KP-100 in INN Recommended List 86 (https://www.who.int/publications/m/item/inn-rl-86). KP-100 is the recombinant human hepatocyte growth factor, HGF, which is currently under clinical development by Kringle Pharma for the treatment of incurable diseases such as acute spinal cord injury and ALS.